Bookbot

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action

Meer over het boek

The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.

Een boek kopen

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action, A.C.B. Cato, H. Schacke, K. Asadullah

Taal
Jaar van publicatie
2002
product-detail.submit-box.info.binding
(Hardcover)
Zodra we het ontdekt hebben, sturen we een e-mail.

Betaalmethoden

Nog niemand heeft beoordeeld.Tarief

Titel
Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action
Taal
Engels
Uitgever
Springer
Jaar van publicatie
2002
Formaat
Hardcover
Aantal pagina's
384
ISBN10
3540432299
ISBN13
9783540432296
Reeks
Aantekening
The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.